Background and aim: Egypt has high prevalence of hepatitis C virus (HCV) infection. This ‎infection may be complicated by serious outcome as liver cirrhosis and ‎hepatic cell carcinoma. Introduction of direct acting analogues (DAAs) for ‎therapy has achieved good results. Aim of this study to evaluate ‎haematological, biochemical and immunological effect of DAAs‎‎.‎
Patients and Methods: ‎‎‎ A total of 100 chronically HCV infected patients were enrolled over one-‎year duration. Complete blood picture, liver function and expression of ‎peripheral mononuclear cells ((CD+3, CD+4, CD3+CD4+, CD3+CD8+, ‎CD3−CD8+ cells)) were evaluated at baseline and 3-month after end of ‎therapy‎‎.‎
Results: Mean age of those patients was 44.87 years and 68% of them was males. ‎All patients received single regimen in form of Sofosbuvir and Dacltasvir ‎for three months. Also, all of them achieved sustained virological response ‎and majority (93%) reported no side effects. There was significant ‎reduction in expression of peripheral mononuclear cells ((CD+3, CD+4, ‎CD3+CD4+, CD3+CD8+, CD3−CD8+ cells)) at 3-months post-therapy‎‎‎‎‎‎‎.
Conclusion: Although combination of Sofosbuvir and Dacltasvir was  safe and ‎effective in management of chronic HCV infection but its effect on the ‎immune cells is still unclear. Further studies are in need to confirm such ‎results‎.